Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GRFS - Grifols SA - ADR - Level III


IEX Last Trade
9.36
0.260   2.778%

Share volume: 4,186,670
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$9.10
0.26
2.86%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
20%
Profitability 26%
Dept financing 20%
Liquidity 34%
Performance 12%
Company vs Stock growth
vs
Performance
5 Days
8.86%
1 Month
20.52%
3 Months
30.45%
6 Months
0   0%
1 Year
-1.06%
2 Year
20.05%
Key data
Stock price
$9.36
P/E Ratio 
37.23
DAY RANGE
N/A - N/A
EPS 
$0.10
52 WEEK RANGE
$5.30 - $12.15
52 WEEK CHANGE
-$0.01
MARKET CAP 
2.442 B
YIELD 
N/A
SHARES OUTSTANDING 
261.425 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,662,042
AVERAGE 30 VOLUME 
$1,830,003
Company detail
CEO:
Region: US
Website: http://www.grifols.com/es/web/international/home
Employees: 10,164
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

for more than 75 years, grifols has been improving the health and well-being of people. our patients are our priority, and our commitment to their health has enabled us to become a global healthcare leader with presence in more than 100 countries. the grifols legacy embodies a spirit of innovation and a forward thinking approach and establish us as an international benchmark in the plasma collection market, the production of plasma derived therapies and transfusion medicine. grifols has three business divisions: bioscience brings together all plasma related activities including research, development, collection, production and sales of life-saving plasma derived therapies. diagnostic provides innovative solutions to support safe and compatible transfusions, monitor therapies, and detect infectious and autoimmune diseases. research novel technologies to further improve treatment outcomes and laboratory efficiency. hospital specializes in non-biological pharmaceutical products. t

Recent news